Journal
STEM CELL REVIEWS AND REPORTS
Volume 16, Issue 3, Pages 541-556Publisher
SPRINGER
DOI: 10.1007/s12015-019-09944-w
Keywords
Mesenchymal stem cells; Exosomes; Breast cancer stem cells; LNA-antimir-142-3p; APC
Funding
- Mashhad University of Medical Sciences, Tehran [931289]
- Tarbiat Modares University, Tehran [931289]
- cancer research center of cancer institute of Iran (Shams cancer charity) [37604-202-01-97]
Ask authors/readers for more resources
Exosomes, nano-sized cell-derived vesicles, have been employed as non-synthetic carriers of various pharmaceutics in numerous studies. As higher expression levels of miR-142-3p and miR-150 in breast cancer stem cells (BCSCs) are associated with their clonogenic and tumorigenic capabilities, the present study aims to exploit the mesenchymal stem cells-derived exosomes (MSCs-Exo) to deliver LNA-antimiR-142-3p into MCF7-derived cancer stem-like cells to suppress expression levels of miR-142-3p and miR-150 in order to reduce clonogenicity and tumorigenicity. Our results indicated that the MSCs-Exo can efficiently deliver the LNA-antimiR-142-3p to breast cancer stem-like cells to reduce the miR-142-3p and miR-150 expression levels. Furthermore, the inhibition of the oncomiRs with the delivery of LNA-antimiR-142-3p resulted in a significant reduction of clone-formation and tumor-initiating abilities of the MCF7-derived cancer stem-like cells. In conclusion, we showed that MSCs-derived exosomes could be used as a feasible nanovehicles to deliver RNA-based therapeutics into BCSCs to improve the cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available